Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | F12 | P00748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13256281 | 0.93 | ADORA3 (0.48) | ADORA3NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3501254 | 0.88 | ADORA1 (0.52) | ADORA3NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL13256183 | 0.87 | MAPK14 (0.54) | ADORA3NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL13256178 | 0.84 | MAPT (0.50) | ADORA3NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL13256172 | 0.82 | SCD (0.57) | ADORA3NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL13256284 | 0.81 | F2 (0.54) | ADORA3NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3500537 | 0.81 | PARP1 (0.54) | ADORA3NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL13256173 | 0.81 | PTGDR2 (0.61) | ADORA3NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL13283501 | 0.79 | ADORA3 (0.49) | ADORA3NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL13256189 | 0.78 | ADORA3 (0.63) | ADORA3NPC1RAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7473783-B2 | Bicyclic pyrazolo protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473783-B2 | Bicyclic pyrazolo protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | MAP3K20, MAP4K2, MAP4K3 | ADORA3 2528/4885NPC1 2951/4885RAB9A 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.